
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc's innovative approach to GPCR oral small molecule drug discovery, powered by its proprietary Native Complex Platform, positions the company well within the rapidly expanding biotechnology market. The anticipated Phase 1 results for SEP-786 and other pipeline candidates in mid-2025 are expected to be significant catalysts, with initial projections estimating around $1.5 billion in annual sales from the CSU indication alone, reflecting the potential of oral therapeutics in a competitive landscape often dominated by injectable formulations. Furthermore, early feedback from specialists indicates positive sentiment towards the launches of SEP-786 and Yorvipath, suggesting a solid foundation for de-risking future development and enhancing pricing flexibility for these treatments.
Bears say
Septerna Inc faces substantial challenges as evident from the unimpressive outcomes of its clinical trials, specifically a Phase 2a trial where serum calcium levels only reached approximately 8 mg/dL, reflecting a less than 50% mean reduction, which raises concerns about the efficacy of its drug candidates. The prevalence of over 50% of non-olfactory GPCR targets being classified as "undruggable" suggests significant limitations in the current technological capabilities, potentially hindering the company's long-term drug discovery efforts. Additionally, the discontinuation of Natpara commercialization by Takeda highlights a broader issue regarding the commercial viability of similar drug candidates in the market, which could adversely impact Septerna's competitive positioning and financial prospects.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares